Subtherapeutic international normalized ratio in warfarin-treated patients increases the risk for symptomatic intracerebral hemorrhage after intravenous thrombolysis

Raymond C.S. Seet, Yi Zhang, S. Arthur Moore, Eelco F. Wijdicks, Alejandro Rabinstein

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Background and Purpose-There is uncertainty whether warfarin-treated patients (despite international normalized ratio <1.7) have increased risks of symptomatic intracerebral hemorrhage after intravenous thrombolysis. Methods-Vascular risk factors, stroke subtype, and outcome measures were compared between warfarin-and nonwarfarin-treated patients undergoing acute thrombolysis within 3 hours of symptom onset. Results-From 212 patients (mean age, 74±14 years; 50% men) studied, 14 (6.5%) had prior warfarin use. After adjusting for age, baseline National Institutes of Health Stroke Scale, and stroke subtype, warfarin-treated patients had significantly increased risks of developing symptomatic intracerebral hemorrhage (adjusted OR, 14.7; 95% CI, 1.3 to 54.3). A trend for poorer stroke recovery and increased mortality was observed in warfarin-treated patients on univariate, but not on multivariable, analyses. Conclusions-Warfarin-treated patients with stroke have increased risks of symptomatic intracerebral hemorrhage after thrombolytic treatment. These data raise safety concerns of thrombolytic treatment in warfarin-treated patients with subtherapeutic international normalized ratio.

Original languageEnglish (US)
Pages (from-to)2333-2335
Number of pages3
JournalStroke
Volume42
Issue number8
DOIs
StatePublished - Aug 1 2011

Fingerprint

International Normalized Ratio
Cerebral Hemorrhage
Warfarin
Stroke
National Institutes of Health (U.S.)
Uncertainty
Outcome Assessment (Health Care)
Safety
Mortality
Therapeutics

Keywords

  • INR
  • intracerebral hemorrhage
  • ischemic stroke
  • warfarin

ASJC Scopus subject areas

  • Clinical Neurology
  • Cardiology and Cardiovascular Medicine
  • Advanced and Specialized Nursing

Cite this

Subtherapeutic international normalized ratio in warfarin-treated patients increases the risk for symptomatic intracerebral hemorrhage after intravenous thrombolysis. / Seet, Raymond C.S.; Zhang, Yi; Moore, S. Arthur; Wijdicks, Eelco F.; Rabinstein, Alejandro.

In: Stroke, Vol. 42, No. 8, 01.08.2011, p. 2333-2335.

Research output: Contribution to journalArticle

@article{3cc63f6f15564e9e92cc89bc3e299bcd,
title = "Subtherapeutic international normalized ratio in warfarin-treated patients increases the risk for symptomatic intracerebral hemorrhage after intravenous thrombolysis",
abstract = "Background and Purpose-There is uncertainty whether warfarin-treated patients (despite international normalized ratio <1.7) have increased risks of symptomatic intracerebral hemorrhage after intravenous thrombolysis. Methods-Vascular risk factors, stroke subtype, and outcome measures were compared between warfarin-and nonwarfarin-treated patients undergoing acute thrombolysis within 3 hours of symptom onset. Results-From 212 patients (mean age, 74±14 years; 50{\%} men) studied, 14 (6.5{\%}) had prior warfarin use. After adjusting for age, baseline National Institutes of Health Stroke Scale, and stroke subtype, warfarin-treated patients had significantly increased risks of developing symptomatic intracerebral hemorrhage (adjusted OR, 14.7; 95{\%} CI, 1.3 to 54.3). A trend for poorer stroke recovery and increased mortality was observed in warfarin-treated patients on univariate, but not on multivariable, analyses. Conclusions-Warfarin-treated patients with stroke have increased risks of symptomatic intracerebral hemorrhage after thrombolytic treatment. These data raise safety concerns of thrombolytic treatment in warfarin-treated patients with subtherapeutic international normalized ratio.",
keywords = "INR, intracerebral hemorrhage, ischemic stroke, warfarin",
author = "Seet, {Raymond C.S.} and Yi Zhang and Moore, {S. Arthur} and Wijdicks, {Eelco F.} and Alejandro Rabinstein",
year = "2011",
month = "8",
day = "1",
doi = "10.1161/STROKEAHA.111.614214",
language = "English (US)",
volume = "42",
pages = "2333--2335",
journal = "Stroke",
issn = "0039-2499",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - Subtherapeutic international normalized ratio in warfarin-treated patients increases the risk for symptomatic intracerebral hemorrhage after intravenous thrombolysis

AU - Seet, Raymond C.S.

AU - Zhang, Yi

AU - Moore, S. Arthur

AU - Wijdicks, Eelco F.

AU - Rabinstein, Alejandro

PY - 2011/8/1

Y1 - 2011/8/1

N2 - Background and Purpose-There is uncertainty whether warfarin-treated patients (despite international normalized ratio <1.7) have increased risks of symptomatic intracerebral hemorrhage after intravenous thrombolysis. Methods-Vascular risk factors, stroke subtype, and outcome measures were compared between warfarin-and nonwarfarin-treated patients undergoing acute thrombolysis within 3 hours of symptom onset. Results-From 212 patients (mean age, 74±14 years; 50% men) studied, 14 (6.5%) had prior warfarin use. After adjusting for age, baseline National Institutes of Health Stroke Scale, and stroke subtype, warfarin-treated patients had significantly increased risks of developing symptomatic intracerebral hemorrhage (adjusted OR, 14.7; 95% CI, 1.3 to 54.3). A trend for poorer stroke recovery and increased mortality was observed in warfarin-treated patients on univariate, but not on multivariable, analyses. Conclusions-Warfarin-treated patients with stroke have increased risks of symptomatic intracerebral hemorrhage after thrombolytic treatment. These data raise safety concerns of thrombolytic treatment in warfarin-treated patients with subtherapeutic international normalized ratio.

AB - Background and Purpose-There is uncertainty whether warfarin-treated patients (despite international normalized ratio <1.7) have increased risks of symptomatic intracerebral hemorrhage after intravenous thrombolysis. Methods-Vascular risk factors, stroke subtype, and outcome measures were compared between warfarin-and nonwarfarin-treated patients undergoing acute thrombolysis within 3 hours of symptom onset. Results-From 212 patients (mean age, 74±14 years; 50% men) studied, 14 (6.5%) had prior warfarin use. After adjusting for age, baseline National Institutes of Health Stroke Scale, and stroke subtype, warfarin-treated patients had significantly increased risks of developing symptomatic intracerebral hemorrhage (adjusted OR, 14.7; 95% CI, 1.3 to 54.3). A trend for poorer stroke recovery and increased mortality was observed in warfarin-treated patients on univariate, but not on multivariable, analyses. Conclusions-Warfarin-treated patients with stroke have increased risks of symptomatic intracerebral hemorrhage after thrombolytic treatment. These data raise safety concerns of thrombolytic treatment in warfarin-treated patients with subtherapeutic international normalized ratio.

KW - INR

KW - intracerebral hemorrhage

KW - ischemic stroke

KW - warfarin

UR - http://www.scopus.com/inward/record.url?scp=79961210540&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79961210540&partnerID=8YFLogxK

U2 - 10.1161/STROKEAHA.111.614214

DO - 10.1161/STROKEAHA.111.614214

M3 - Article

C2 - 21659639

AN - SCOPUS:79961210540

VL - 42

SP - 2333

EP - 2335

JO - Stroke

JF - Stroke

SN - 0039-2499

IS - 8

ER -